This logic has manifested in the newly released guidance to companies interested in pursuing a broad listing for cancer immunotherapies. An expectation of no net cost. Patients, you waited nine years for this, and it was granted on the basis that your treatment cost the government nothing. That is what your life is worth.
Watching this system has become like cheering for an elephant on a unicycle
June 24, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Can GLP-1s be more transformative than AI - one person believes they already are
July 14, 2026 - - Latest News -
The age-old argument for supermarket pharmacies misses the point, and the risks
July 14, 2026 - - Latest News -
Pharmacy Guild rejects Grattan Institute report, describing community pharmacies as essential health providers
July 13, 2026 - - Latest News -
Immutep cancer candidate shows strong median survival in lung cancer as company consider conflicting trial results
July 13, 2026 - - Australian Biotech -
OncoSil Medical establishes scalable Australian production after successful manufacturing validation
July 13, 2026 - - Australian Biotech -
SCENESSE gains Canadian approval offering long term protection for patients with rare disorder
July 13, 2026 - - Australian Biotech -
Patrys and Yale agree revenue share to advance deoxymab platform
July 13, 2026 - - Australian Biotech

